Ziprasidone Mesylate Injection, Powder, Lyophilized, For Solution
Product Images NDC 72205-205

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ziprasidone Mesylate (NDC 72205-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zipra-inj-10s-carton-label (Zipra Inj 10s Carton Label)

Ziprasidone Mesylate for Injection is a sterile medication available in a box containing 10 single-dose vials for intramuscular use only. The NDC number is 72205-205-07, and it is produced by NOVADOZ. Users are advised to protect the contents from light. No other relevant information was provided.*

FDA Label Image

Str (Zipra Inj Structure)

FDA Label Image

Zipra-inj-vial-label (Zipra Inj Vial Label)

This is a product description for Ziprasidone Mesylate for Injection. It contains 2 mg of Ziprasidone and 4.7 mg of Methanesulfonic acid and is administered intramuscularly. The powder must be reconstituted with 1.2 mL of sterile water for injection. The resulting solution has a concentration of 20 mg/mL. Dosage and usage information should be obtained from accompanying prescribing information. This product is distributed by Novador Pharmaceuticals and the reconstitution process should be done in light-protected areas.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.